INT102645

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 2002
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 4
Disease Relevance 2.81
Pain Relevance 0.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein transporter activity (COX18) mitochondrion (COX18)
COX18 (Homo sapiens)
Pain Link Frequency Relevance Heat
Snapping jaw 4 86.64 High High
cINOD 8 79.20 Quite High
Pain 1 69.00 Quite High
COX2 9 25.00 Low Low
Disease Link Frequency Relevance Heat
Apoptosis 14 96.72 Very High Very High Very High
Skin Cancer 2 89.44 High High
Esophageal Cancer 4 87.24 High High
Colorectal Cancer 4 87.16 High High
Cancer 5 82.76 Quite High
INFLAMMATION 3 78.64 Quite High
Necrosis 1 76.40 Quite High
Temporomandibular Joint Syndrome 4 75.36 Quite High
Synovitis 1 69.56 Quite High
Arthralgia 1 69.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
U0126, a specific inhibitor of the ERK-activating kinases MEK-1/-2, prevented the activation of ERK induced by NS-398 and blocked the increase in COX-2 protein expression seen when HT29 cells were treated with NS-398 alone.
Negative_regulation (blocked) of Gene_expression (expression) of COX-2 protein
1) Confidence 0.12 Published 2002 Journal Int. J. Cancer Section Abstract Doc Link 11992399 Disease Relevance 0.61 Pain Relevance 0.27
NS-398 dose-dependently decreased the levels of COX-2 mRNA, COX-2 protein, nuclear NF-kappaB protein and production of PGF(1alpha) and increased the cytoplasmic IkappaB protein.
Negative_regulation (decreased) of Gene_expression (levels) of COX-2 protein
2) Confidence 0.12 Published 2009 Journal Cancer Invest. Section Abstract Doc Link 19160097 Disease Relevance 0.82 Pain Relevance 0.13
Expression of COX-2 mRNA was measured by RT-PCR and COX-2 protein levels with Western blot analysis.
Negative_regulation (measured) of Gene_expression (levels) of COX-2 protein
3) Confidence 0.12 Published 2009 Journal Cancer Invest. Section Abstract Doc Link 19160097 Disease Relevance 0.88 Pain Relevance 0.16
Pre-treatment with pyrolidine dithiocarbamate (PDTC), one of the NF-kappaB inhibitors, prevented binding to the COX-2 promoter and expression of COX-2 protein in response to TNF-alpha.
Negative_regulation (prevented) of Gene_expression (expression) of COX-2 protein
4) Confidence 0.12 Published 2007 Journal J. Dent. Res. Section Abstract Doc Link 17384033 Disease Relevance 0.50 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox